Detail akcie Oxford BioDynam Rg online

Business Summary: Oxford BioDynamics Plc is a United Kingdom-based biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases. The Company is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch PSE, Specimen Submission Kit, and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test which predicts an individual patient’s therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The Specimen Submission Kit is used for collecting samples from any location. The EpiSwitch platform offers reproducibly translating three-dimensional (3D) genome regulation for clinical applications. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.
Financial Summary: BRIEF: For the fiscal year ended 30 September 2025, Oxford Biodynamics PLC revenues increased 72% to L1.1M. Net loss decreased 4% to L11.2M. Revenues reflect USA segment increase from L459K to L958K. Lower net loss reflects biomarker research and development segment loss decrease of 14% to L11.1M. Basic Earnings per Share excluding Extraordinary Items increased from -L0.04523 to -L0.00804.